Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Apr 26, 2025
Date Accepted: Dec 9, 2025

The final, peer-reviewed published version of this preprint can be found here:

Assessment of Blood Glucose Measurement Using New Noninvasive Technology: Protocol and Methodology

Suradji EW, Lim A, Zhou E, Li-Feng Z, Fredicia F, Dianky A, Pasaribu P, Masayoshi EG, Santoso M, Dhaliwal SS, Seng BA

Assessment of Blood Glucose Measurement Using New Noninvasive Technology: Protocol and Methodology

JMIR Res Protoc 2026;15:e76558

DOI: 10.2196/76558

PMID: 41505712

PMCID: 12782458

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Assessment of Blood Glucose measurement using New Non-Invasive Technology: Protocol & Methodology

  • Eka Widrian Suradji; 
  • Amos Lim; 
  • Entong Zhou; 
  • Zhang Li-Feng; 
  • Fredicia Fredicia; 
  • Amanda Dianky; 
  • Puspasari Pasaribu; 
  • Ernset Gamaliel Masayoshi; 
  • Mardi Santoso; 
  • Satvinder Singh Dhaliwal; 
  • Bin Ang Seng

ABSTRACT

Background:

Diabetes Mellitus is a major non-communicable disease with significant increase in prevalence, especially in low and middle-income countries. The latest IDF Diabetes Atlas (2025) reports that 11,1%, or about 1 in 9, of the adult population (20-79 years old) is living with diabetes, with over 4 in 10 unaware that they have the condition. This Prevalence is expected to increase to 1 in 8 adults by the year 2050. Early diagnosis and treatment of Diabetes reduces the risk and slows the progression of debilitating complications such as amputation, vision loss, and renal failure, cardiovascular disease, dementia, some cancers, and infections such as tuberculosis and severe COVID-19. Current screening methods for diabetes are invasive and costly. This has limited its more widespread utilisation especially in a high-density population, middle-low income country such as Indonesia. Blood Glucose Evaluation and Monitoring (BGEM) is a machine learning (ML) algorithm developed by Actxa to analyze Photoplethysmography (PPG) data from wearable devices for diabetic risk assessment. Its non-invasive and user-friendly nature makes it a strong candidate for fulfilling the need for a diabetes screening tool.

Objective:

The Aim of this study is to enhance BGEM’s performance on a large and diverse data set with an emphasis on the detailed blood sugar fluctuation, also known as glycaemic variability, under semi-controlled conditions in an Indonesian population.

Methods:

Adult subjects aged 18 years old and above, either with a diabetic or non-diabetic history that resides in Greater Jakarta Area, Indonesia were recruited. The study will explore BGEM blood glucose prediction capabilities compared to laboratory blood analysis from capillary or plasma samples at after fasting, 1 hour, 2 hour and 3 hours after meal. In addition to PPG and blood data collection, anthropological measurement, a standardize questionnaire on activity, demographic information and diabetic status were also conducted to provide a more complete dataset.

Results:

A total of 885 subjects were included into the study from June to October 2024, 473 were diabetic subjects and 412 were non-diabetic subjects. The blood sugar profiles of the subjects will be studied and analysed. BGEM’s performance will be assessed on this Indonesian dataset on glycaemic variability.

Conclusions:

This protocol paper outlines the methodology designed for subject’s blood sugar profiles especially on glycaemic variability in order to evaluate BGEM, a PPG-based AI model designed to estimate blood glucose levels and diabetic risk. The clinical trial was conducted on both diabetic (DM) and non-diabetic (non-DM) Indonesian subjects, while considering various influencing factors. The results will provide objective evidence on the validity and use of a non-invasive technique for the measurement of blood sugar levels using wearables. Clinical Trial: Clinical trial registration NCT06642467 Institutional Review Board of Ukrida faculty of medicine & health sciences ethical committee 1779/SLKE/IM/UKKW /FKIK/KEPK /VII/2024


 Citation

Please cite as:

Suradji EW, Lim A, Zhou E, Li-Feng Z, Fredicia F, Dianky A, Pasaribu P, Masayoshi EG, Santoso M, Dhaliwal SS, Seng BA

Assessment of Blood Glucose Measurement Using New Noninvasive Technology: Protocol and Methodology

JMIR Res Protoc 2026;15:e76558

DOI: 10.2196/76558

PMID: 41505712

PMCID: 12782458

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.